Seroatlas · Human Serome Atlas

TFPI

Tissue factor pathway inhibitor

Also known as: EPI, LACI, TFI, TFPI1, TFPI1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P10646
Gene
TFPI
Ensembl
ENSG00000003436
Chromosome
2
Canonical length
304 aa
Protein class
Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins
Secretome location
Secreted to blood

OverviewNCBI Gene

This gene encodes a Kunitz-type serine protease inhibitor that regulates the tissue factor (TF)-dependent pathway of blood coagulation. The coagulation process initiates with the formation of a factor VIIa-TF complex, which proteolytically activates additional proteases (factors IX and X) and ultimately leads to the formation of a fibrin clot. The product of this gene inhibits the activated factor X and VIIa-TF proteases in an autoregulatory loop. Inhibition of the encoded protein restores hemostasis in animal models of hemophilia. This gene encodes multiple protein isoforms that differ in their inhibitory activity, specificity and cellular localization. [provided by RefSeq, Jul 2016]

Canonical amino-acid sequenceUniProt

304 residues, UniProt reviewed canonical sequence.

>P10646|TFPI
     1  MIYTMKKVHA LWASVCLLLN LAPAPLNADS EEDEEHTIIT DTELPPLKLM HSFCAFKADD
    61  GPCKAIMKRF FFNIFTRQCE EFIYGGCEGN QNRFESLEEC KKMCTRDNAN RIIKTTLQQE
   121  KPDFCFLEED PGICRGYITR YFYNNQTKQC ERFKYGGCLG NMNNFETLEE CKNICEDGPN
   181  GFQVDNYGTQ LNAVNNSLTP QSTKVPSLFE FHGPSWCLTP ADRGLCRANE NRFYYNSVIG
   241  KCRPFKYSGC GGNENNFTSK QECLRACKKG FIQRISKGGL IKTKRKRKKQ RVKIAYEEIF
   301  VKNM

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TFPI can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.45
Highest tissue expression
254 nTPM

Expression across tissuesHPA

Tissue

  • liver: 254 nTPM
  • placenta: 180 nTPM
  • lung: 115 nTPM
  • adipose tissue: 63 nTPM
  • gallbladder: 54 nTPM
  • kidney: 53 nTPM

Single-cell type

  • extravillous trophoblasts: 3,874 nCPM
  • lymphatic endothelial cells: 2,527 nCPM
  • syncytiotrophoblasts: 1,286 nCPM
  • alveolar cells type 2: 669 nCPM
  • hepatocytes: 594 nCPM
  • myosatellite cells: 517 nCPM

Immune cell

  • basophil: 3.3 nTPM
  • plasmacytoid DC: 2.8 nTPM
  • total PBMC: 2.7 nTPM
  • naive B-cell: 1.5 nTPM
  • neutrophil: 1.4 nTPM
  • eosinophil: 1 nTPM

Brain region

  • choroid plexus: 22 nTPM
  • medulla oblongata: 21 nTPM
  • cerebellum: 16 nTPM
  • cerebral cortex: 15 nTPM
  • hippocampal formation: 15 nTPM
  • pons: 14 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TFPI.

Disease | AutoantibodyPubMed

Conditions in which antibodies against TFPI are reported. Each links to that disease's full target list.

ReferencesPubMed · IEDB

Publications for TFPI from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.56
gnomAD pLI
0.25
gnomAD missense Z
1.31
DepMap mean gene effect
0.14
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TFPI as an antibody target. Whether an autoantibody or antibody against TFPI could matter depends on whether native TFPI is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TFPI is annotated as secreted, so native TFPI circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label TFPI as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TFPI. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...